Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set.
Monica ZiffGabrielle LawsonDunnya De-SilvaSimon CheesmanCharalampia KyriakouShameem MahmoodXenofon PapanikolaouNeil RabinSajitha SachchithananthanJonathan SiveAshutosh D WechalekarKwee L YongRakesh PopatPublished in: Leukemia & lymphoma (2021)